Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV

Combination therapy with ledipasvir and sofosbuvir (LDV/SOF), direct-acting antiviral agents, is highly effective against hepatitis C virus genotype 1 infection. Although LDV/SOF is safer than conventional treatment, reports have indicated that LDV/SOF was discontinued in certain cases due to severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadokoro, Tomoko, Morishita, Asahiro, Fujita, Koji, Oura, Kyoko, Sakamoto, Teppei, Nomura, Takako, Tani, Joji, Yoneyama, Hirohito, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938499/
https://www.ncbi.nlm.nih.gov/pubmed/29279506
http://dx.doi.org/10.2169/internalmedicine.9744-17
_version_ 1783320796152725504
author Tadokoro, Tomoko
Morishita, Asahiro
Fujita, Koji
Oura, Kyoko
Sakamoto, Teppei
Nomura, Takako
Tani, Joji
Yoneyama, Hirohito
Masaki, Tsutomu
author_facet Tadokoro, Tomoko
Morishita, Asahiro
Fujita, Koji
Oura, Kyoko
Sakamoto, Teppei
Nomura, Takako
Tani, Joji
Yoneyama, Hirohito
Masaki, Tsutomu
author_sort Tadokoro, Tomoko
collection PubMed
description Combination therapy with ledipasvir and sofosbuvir (LDV/SOF), direct-acting antiviral agents, is highly effective against hepatitis C virus genotype 1 infection. Although LDV/SOF is safer than conventional treatment, reports have indicated that LDV/SOF was discontinued in certain cases due to severe skin disorders. A 68-year-old woman presented with a rash after starting LDV/SOF treatment. We interrupted LDV/SOF and began the oral administration of prednisolone (PSL). After the rash improved, we re-started LDV/SOF with PSL. After treatment, the rash clearly improved; we checked for a sustained virologic response 12 weeks after treatment. Steroids may therefore be an effective treatment option for controlling the side effects of LDV/SOF.
format Online
Article
Text
id pubmed-5938499
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-59384992018-05-08 Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV Tadokoro, Tomoko Morishita, Asahiro Fujita, Koji Oura, Kyoko Sakamoto, Teppei Nomura, Takako Tani, Joji Yoneyama, Hirohito Masaki, Tsutomu Intern Med Case Report Combination therapy with ledipasvir and sofosbuvir (LDV/SOF), direct-acting antiviral agents, is highly effective against hepatitis C virus genotype 1 infection. Although LDV/SOF is safer than conventional treatment, reports have indicated that LDV/SOF was discontinued in certain cases due to severe skin disorders. A 68-year-old woman presented with a rash after starting LDV/SOF treatment. We interrupted LDV/SOF and began the oral administration of prednisolone (PSL). After the rash improved, we re-started LDV/SOF with PSL. After treatment, the rash clearly improved; we checked for a sustained virologic response 12 weeks after treatment. Steroids may therefore be an effective treatment option for controlling the side effects of LDV/SOF. The Japanese Society of Internal Medicine 2017-12-27 2018-04-15 /pmc/articles/PMC5938499/ /pubmed/29279506 http://dx.doi.org/10.2169/internalmedicine.9744-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Tadokoro, Tomoko
Morishita, Asahiro
Fujita, Koji
Oura, Kyoko
Sakamoto, Teppei
Nomura, Takako
Tani, Joji
Yoneyama, Hirohito
Masaki, Tsutomu
Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
title Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
title_full Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
title_fullStr Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
title_full_unstemmed Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
title_short Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
title_sort severe steroid-responsive skin disorders related to ledipasvir and sofosbuvir for hcv
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938499/
https://www.ncbi.nlm.nih.gov/pubmed/29279506
http://dx.doi.org/10.2169/internalmedicine.9744-17
work_keys_str_mv AT tadokorotomoko severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT morishitaasahiro severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT fujitakoji severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT ourakyoko severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT sakamototeppei severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT nomuratakako severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT tanijoji severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT yoneyamahirohito severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv
AT masakitsutomu severesteroidresponsiveskindisordersrelatedtoledipasvirandsofosbuvirforhcv

Ejemplares similares